ADC Shows Effectiveness in SCLC.
Results from a phase I trial presented during the 2015 European Cancer Congress suggest that an experimental antibody-drug conjugate, rovalpituzumab tesirine, may be effective against recurrent small cell lung cancer, for which there are few treatment options.